Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2018-12-20 Report Publication Anno…
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "Onxeo annonce son calendrier financier 2019" (Onxeo announces its 2019 financial calendar) and explicitly lists future dates for key financial events: Annual Results 2018, General Meeting (AGM), and H1 2019 Results. This document is an announcement detailing the schedule of future corporate events, rather than the reports themselves (like 10-K, ER, or IR). Since it announces the schedule for reports and the AGM, it fits best under the category for announcing the publication of reports or general regulatory updates. Given the specific nature of announcing a schedule of future reports, it is most accurately classified as a Report Publication Announcement (RPA), as it informs stakeholders about *when* reports will be released, even though it also mentions the AGM date. It is not the AGM material itself (AGM-R) or the actual financial results (ER/IR).
2018-12-20 French
Communicated under the obligation to provide permanent information / Other communications
Legal Proceedings Report Classification · 1% confidence The document is a press release announcing that Onxeo received an Intent-to-Grant Notice from the European Patent Office (EPO) for a new patent protecting the combination of AsiDNA™ with any PARP inhibitor. This announcement relates to intellectual property and legal/regulatory protection for a drug candidate. It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a formal shareholder vote result (DVA). Since it concerns a specific legal/regulatory development regarding intellectual property protection, it fits best under the category for Legal Proceedings Report (LTR), as patent grants/notices are significant legal milestones, or potentially Regulatory Filings (RNS) as a general announcement. Given the specific nature of patent protection news, LTR is a strong candidate, but RNS is often used for general regulatory/legal updates that aren't formal litigation reports. However, looking at the definitions, LTR is for 'significant lawsuits, regulatory actions, or legal matters'. A patent grant notice is a positive legal matter. Since there isn't a specific 'IP/Patent Update' category, and this is a formal announcement of a regulatory/legal step, RNS (Regulatory Filings - general fallback) is the safest classification, although LTR is plausible if the scope of LTR is interpreted broadly to include IP protection milestones. Given the context of a press release announcing a patent notice, RNS serves as the most appropriate general regulatory announcement category when a more specific one is missing.
2018-12-18 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Onxeo S.A. dated December 18, 2018, announcing that it has received notification from the European Patent Office (OEB) of its intention to grant a new patent (EP3325623) protecting the combination of AsiDNA™ with any PARP inhibitor. This announcement concerns intellectual property rights and patent protection, which is a form of corporate development or strategic update. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a proxy statement (DEF 14A). Since the core subject is the strengthening of the intellectual property portfolio through a patent grant notification, it best fits under general corporate news or regulatory/legal updates. Given the options, this type of announcement, which details a specific legal/IP development, is most closely aligned with general corporate announcements that don't fit the specific financial or governance categories. However, since it is a specific announcement about a legal/IP asset, and not a general regulatory filing (RNS) or a legal proceeding (LTR), we must check if there is a better fit. None of the provided codes explicitly cover 'Patent Grant Notification'. It is a specific corporate update. Since it is not a financial report, management discussion, or governance document, and it is not a transaction (TAR, SHA, POS), the most appropriate general category for a significant, non-financial, non-governance announcement that is not a standard regulatory filing fallback is often related to the company's core assets or strategy. Given the available codes, and recognizing this is a specific announcement about an asset's protection, it is not a standard 'Legal Proceedings Report' (LTR) as it is a positive IP development, not a lawsuit. It is not a 'Capital/Financing Update' (CAP). It is a specific corporate announcement. In the absence of a dedicated 'Intellectual Property' or 'Patent' code, and given that it is a formal announcement of a significant corporate development, it falls best under the general 'Regulatory Filings' (RNS) as a fallback for specific, non-standard announcements, or potentially 'LTR' if interpreted broadly as a legal/regulatory outcome. Given the context of patent protection, which is a key asset announcement, and lacking a better fit, RNS (Regulatory Filings/Miscellaneous Announcement) is the safest fallback. However, if we interpret the announcement as relating to the company's core asset development and protection, it is a significant corporate event. Since it is a formal announcement of a legal/IP development, and not a financial report, I will classify it as RNS as the most appropriate general regulatory/corporate announcement category.
2018-12-18 French
Communicated under the obligation to provide permanent information / Other communications
Legal Proceedings Report Classification · 1% confidence The document is a press release dated December 13, 2018, reporting on a specific legal decision from the Paris Court of Appeal regarding a lawsuit involving Onxeo and its former partners. It details the outcome of the litigation, including financial implications. This type of announcement, focusing on significant legal proceedings, directly matches the definition for Legal Proceedings Report (LTR). It is not a comprehensive annual/interim report (10-K/IR), an earnings release (ER), or a general regulatory filing (RNS), as it addresses a very specific, material legal event.
2018-12-13 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is a press release from Onxeo dated December 13, 2018, announcing a legal decision from the Paris Court of Appeal regarding a dispute with SpeBio B.V. and SpePharm. The content focuses entirely on the outcome of litigation, including financial penalties and next steps regarding appeals. This subject matter—updates on significant lawsuits or regulatory actions—directly corresponds to the definition of a Legal Proceedings Report (LTR). It is not an Annual Report (10-K), an Earnings Release (ER), or a general regulatory filing (RNS), as it details a specific legal event.
2018-12-13 French
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Capital/Financing Update Classification · 1% confidence The document is a press release dated December 3, 2018, announcing the termination of one liquidity contract (with CM-CIC SECURITIES) and the immediate implementation of a new liquidity contract (with Kepler Cheuvreux). This action relates to the management of the company's share liquidity, which falls under corporate financing or capital structure activities. It is not a full annual report (10-K), an earnings release (ER), or a formal shareholder vote result (DVA). Since it details a specific financing/capital management arrangement (liquidity contract), the most appropriate category is Capital/Financing Update (CAP). It is a specific announcement, not a general regulatory filing fallback (RNS).
2018-12-03 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.